1
|
Shahcheraghi SH, Alimardani M, Lotfi M, Lotfi M, Uversky VN, Guetchueng ST, Palakurthi SS, Charbe NB, Hromić-Jahjefendić A, Aljabali AAA, Gadewar MM, Malik S, Goyal R, El-Tanani M, Mishra V, Mishra Y, Tambuwala MM. Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives. Pathol Res Pract 2024; 257:155285. [PMID: 38653089 DOI: 10.1016/j.prp.2024.155285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 03/28/2024] [Accepted: 03/30/2024] [Indexed: 04/25/2024]
Abstract
Glioblastoma, a highly lethal form of brain cancer, is characterized by its aggressive growth and resistance to conventional treatments, often resulting in limited survival. The response to therapy is notably influenced by various patient-specific genetic factors, underscoring the disease's complexity. Despite the utilization of diverse treatment modalities such as surgery, radiation, and chemotherapy, many patients experience local relapse, emphasizing the critical need for improved therapeutic strategies to effectively target these formidable tumors. Recent years have witnessed a surge in interest in natural products derived from plants, particularly alkaloids, for their potential anticancer effects. Alkaloids have shown promise in cancer chemotherapy by selectively targeting crucial signaling pathways implicated in tumor progression and survival. Specifically, they modulate the NF-κB and MAPK pathways, resulting in reduced tumor growth and altered gene expression across various cancer types. Additionally, alkaloids exhibit the capacity to induce cell cycle arrest, further impeding tumor proliferation in several malignancies. This review aims to delineate recent advances in understanding the pathology of glioblastoma multiforme (GBM) and to explore the potential therapeutic implications of alkaloids in managing this deadly disease. By segregating discussions on GBM pathology from those on alkaloid-based therapies, we provide a structured overview of the current challenges in GBM treatment and the promising opportunities presented by alkaloid-based interventions. Furthermore, we briefly discuss potential future directions in GBM research and therapy beyond alkaloids, including emerging treatment modalities or areas of investigation that hold promise for improving patient outcomes. In conclusion, our efforts offer hope for enhanced outcomes and improved quality of life for GBM patients through alkaloid-based therapies. By integrating insights from pathology and therapeutic perspectives, we underscore the significance of a comprehensive approach in addressing this devastating disease.
Collapse
Affiliation(s)
- Seyed Hossein Shahcheraghi
- Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | - Maliheh Alimardani
- Medical Genetics Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Malihe Lotfi
- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Marzieh Lotfi
- Abortion Research Center, Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | - Vladimir N Uversky
- Department of Molecular Medicine and USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
| | - Stephanie Tamdem Guetchueng
- Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, PO Box 6163, Yaoundé, Cameroon
| | - Sushesh Shrivastsa Palakurthi
- Department of Pharmaceutical Sciences, Irma Lerma Rangel School Of Pharmacy, Texas A&M University, Kingsville, TX 78363, USA
| | - Nitin B Charbe
- Center for Pharmacometrics & Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA
| | - Altijana Hromić-Jahjefendić
- Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka cesta 15, Sarajevo 71000, Bosnia and Herzegovina
| | - Alaa A A Aljabali
- Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid, Jordan
| | - Manoj M Gadewar
- Department of Pharmacology, School of medical and allied sciences, K.R. Mangalam University, Gurgaon, Haryana 122103, India
| | - Sumira Malik
- Amity Institute of Biotechnology, Amity University Jharkhand, Ranchi, India
| | - Rohit Goyal
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology & Management Sciences, Solan, India
| | - Mohamed El-Tanani
- Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates
| | - Vijay Mishra
- School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India
| | - Yachana Mishra
- Department of Zoology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab 144411, India
| | - Murtaza M Tambuwala
- Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates; Lincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK.
| |
Collapse
|
2
|
Jin Y, Zhang J, Pan Y, Shen W. Berberine Suppressed the Progression of Human Glioma Cells by Inhibiting the TGF-β1/SMAD2/3 Signaling Pathway. Integr Cancer Ther 2022; 21:15347354221130303. [PMID: 36255058 PMCID: PMC9583234 DOI: 10.1177/15347354221130303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Background: Previous studies have shown that berberine can inhibit glioma progression,
although the underlying molecular mechanisms needed to be explored further.
The aim of this study was to evaluate the suppressive effects of berberine
on human glioma cells, and identify the underlying signaling pathways. Material and Methods: The cytotoxic effect of different concentrations of berberine against normal
human glial cells (HEB) and 4 glioma cell lines was evaluated by the CCK-8
assay. Apoptosis was assayed by flow cytometry. In vitro migration and
invasion were analyzed by the wound healing and transwell assays. The
expression levels of specific proteins were measured by western blotting and
ELISA. Results: Berberine significantly inhibited the proliferation of human glioma U-87
cells, and induced apoptosis in the U-87 and LN229 cells by downregulating
Bcl-2, and upregulating Bax and caspase-3. In addition, berberine also
inhibited migration and invasion of the glioma cells. Furthermore, berberine
exerted its effects on the proliferation, migration, invasion, and apoptosis
of glioma cells by inhibiting the TGF-β1/SMAD2/3 signaling pathway, and
exogenous TGF-β abrogated the pro-apoptotic and anti-oncogenic effects of
berberine. Conclusions: Berberine inhibits glioma progression by targeting the TGF-β1/SMAD2/3
signaling pathway.
Collapse
Affiliation(s)
- Yun Jin
- Tongxiang First People’s Hospital,
Tongxiang, Zhejiang, China
| | - Jiawei Zhang
- Tongxiang First People’s Hospital,
Tongxiang, Zhejiang, China
| | - Yunfeng Pan
- Tongxiang First People’s Hospital,
Tongxiang, Zhejiang, China
| | - Wangzhen Shen
- Tongxiang First People’s Hospital,
Tongxiang, Zhejiang, China,Wangzhen Shen, Department of Neurosurgery,
Tongxiang First People’s Hospital, No. 1918, Jiaochang East Road, Zhendong New
District, Tongxiang City, Zhejiang 314500, China.
| |
Collapse
|
3
|
Lin CY, Liu YS, Pan KT, Chen CB, Hung CF, Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. Sci Rep 2021; 11:12277. [PMID: 34112836 PMCID: PMC8192539 DOI: 10.1038/s41598-021-91021-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 04/19/2021] [Indexed: 12/21/2022] Open
Abstract
Drug-eluting bead transarterial chemoembolization (DEB-TACE) is the most common treatment for unresectable hepatocellular carcinoma (HCC). However, the effect of drug loading concentration and microsphere size on treatment outcomes remains unclear. This retrospective study compares the outcomes of 87 HCC patients who underwent DEB-TACE with half-loaded or full-loaded doxorubicin (maximum capacity 50 mg/mL) in 75-µm or 100-µm microspheres. Treatment with 100-μm microspheres resulted in significantly lower rates of procedure-related complications (6.6% vs. 26.9%; P < 0.05), post-embolization syndrome (32.8% vs. 61.5%, P < 0.05), SIR complications (32.8% vs. 61.5%; P < 0.01) and adverse events involving abdominal pain (19.7% vs. 42.3%; P < 0.05). Half-load doxorubicin microspheres resulted in greater treatment response (OR, 4.00; 95% CI 1.06–15.13; P, 0.041) and shorter hospital stays (OR, − 1.72; 95% CI − 2.77–0.68; P, 0.001) than did microspheres loaded to full capacity. Stratified analysis further showed that patients treated with 100-μm half-load doxorubicin microspheres had a higher CR (63.6% vs 18.0%) and ORR (90.9 vs 54.0%) and a shorter hospital stay (1.6 ± 1.3 vs 4.2 ± 2.3 days) than did those treated with full-load microspheres (P < 0.05). Thus, the drug-loading concentration of microspheres in DEB-TACE should be carefully considered.
Collapse
Affiliation(s)
- Chia-Ying Lin
- Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138 Sheng Li Road, Tainan, 704, Taiwan, ROC
| | - Yi-Sheng Liu
- Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138 Sheng Li Road, Tainan, 704, Taiwan, ROC
| | - Kuang-Tse Pan
- Department of Imaging and Intervention, Chang Gung Medical Foundation-Chang Gung Memorial Hospital, Linkou, No.5 FuXing Street, GueiShan, TaoYuan County, 333, Taiwan, ROC
| | - Chia-Bang Chen
- Department of Radiology, Chang-Hua Christian Hospital, No. 135, Nan-Xiao Street, Changh-Hua City, Changhua County, 500, Taiwan, ROC
| | - Chein-Fu Hung
- Department of Imaging and Intervention, Chang Gung Medical Foundation-Chang Gung Memorial Hospital, Linkou, No.5 FuXing Street, GueiShan, TaoYuan County, 333, Taiwan, ROC.
| | - Chen-Te Chou
- Department of Radiology, Chang-Hua Christian Hospital, No. 135, Nan-Xiao Street, Changh-Hua City, Changhua County, 500, Taiwan, ROC. .,School of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan, ROC. .,Department of Molecular Biotechnology, College of Biotechnology and Bioresources, Dayeh University, Changhua City, Taiwan, ROC.
| |
Collapse
|
4
|
Xie Q, Li H, Lu D, Yuan J, Ma R, Li J, Ren M, Li Y, Chen H, Wang J, Gong D. Neuroprotective Effect for Cerebral Ischemia by Natural Products: A Review. Front Pharmacol 2021; 12:607412. [PMID: 33967750 PMCID: PMC8102015 DOI: 10.3389/fphar.2021.607412] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Accepted: 03/08/2021] [Indexed: 12/12/2022] Open
Abstract
Natural products have a significant role in the prevention of disease and boosting of health in humans and animals. Stroke is a disease with high prevalence and incidence, the pathogenesis is a complex cascade reaction. In recent years, it’s reported that a vast number of natural products have demonstrated beneficial effects on stroke worldwide. Natural products have been discovered to modulate activities with multiple targets and signaling pathways to exert neuroprotection via direct or indirect effects on enzymes, such as kinases, regulatory receptors, and proteins. This review provides a comprehensive summary of the established pharmacological effects and multiple target mechanisms of natural products for cerebral ischemic injury in vitro and in vivo preclinical models, and their potential neuro-therapeutic applications. In addition, the biological activity of natural products is closely related to their structure, and the structure-activity relationship of most natural products in neuroprotection is lacking, which should be further explored in future. Overall, we stress on natural products for their role in neuroprotection, and this wide band of pharmacological or biological activities has made them suitable candidates for the treatment of stroke.
Collapse
Affiliation(s)
- Qian Xie
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Hongyan Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Danni Lu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jianmei Yuan
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Rong Ma
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jinxiu Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Mihong Ren
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Yong Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Hai Chen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jian Wang
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu, China.,School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Daoyin Gong
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
5
|
Liu Z, Chen Y, Gao H, Xu W, Zhang C, Lai J, Liu X, Sun Y, Huang H. Berberine Inhibits Cell Proliferation by Interfering with Wild-Type and Mutant P53 in Human Glioma Cells. Onco Targets Ther 2020; 13:12151-12162. [PMID: 33262612 PMCID: PMC7699991 DOI: 10.2147/ott.s279002] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 11/04/2020] [Indexed: 12/21/2022] Open
Abstract
Introduction Glioma is the most common malignant brain tumor. TP53 is the most common mutant gene in human cancer. Wild-type p53 (wtp53) is a tumor suppressor protein whereas mutant p53 (mutp53) is an oncoprotein that promotes tumor cell proliferation. Our aim was to examine the inhibitory effects of berberine on the proliferation of human glioma cells via regulation of wtp53, mutp53, and their downstream molecules. Methods We selected wtp53 cells (U87 cells) and mutp53 cells (U251 cells termed p53 R273H) to examine the inhibitory effects of berberine on human glioma cells. We used the CCK-8 kit to detect the toxic effect of berberine. Flow cytometry was used to detect the effect of berberine. Clone formation test was used to test the inhibitory effect of berberine on the proliferation of glioma cells. Western blot was used to detect the changes of related proteins such as p53, p-p53, p21 and cyclin D1. Lentivirus transduction was used to transduce wild-type p53 into U251 cells to further examine the effect of berberine. The nude mouse subcutaneous tumor model was used to detect the effect of berberine on inhibiting the proliferation of glioma cells in vivo. Results Berberine promoted the phosphorylation of wtp53, increased the expression of p21 protein, reduced cyclin D1 content, and caused G1 phase arrest in U87 cells. Berberine also reduced mutp53 content and caused G2 phase arrest in U251 cells with a concurrent decrease in p21, cyclin D1, and cyclin B1 content. Transduction with wtp53 enhanced the effects on cell cycle arrest. Further, berberine significantly inhibited glioma growth in vivo mouse tumor model. Discussion Glioma is a group of heterogeneous brain tumors with unique biological and clinical characteristics. Berberine can inhibit glioma cells through a variety of ways. Our research indicated that berberine inhibited the proliferation of glioma cells by interfering with wtp53 and mutp53. This indicates that berberine could be used as a potential drug to treat wild-type and mutant p53 glioma.
Collapse
Affiliation(s)
- Ziqiang Liu
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Yong Chen
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Haijun Gao
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Weidong Xu
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Chaochao Zhang
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Jiacheng Lai
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Xingxing Liu
- Department of Internal Medicine, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Yuxue Sun
- Department of Neurosurgery, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China
| | - Haiyan Huang
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China
| |
Collapse
|